Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Eisai Inc.
Condition: Unresectable Stage III, Stage IV Melanoma
NCT01136967
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: few_sites_large_trial_signal | rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.